{"id":492402,"date":"2021-05-12T16:11:02","date_gmt":"2021-05-12T20:11:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/"},"modified":"2021-05-12T16:11:02","modified_gmt":"2021-05-12T20:11:02","slug":"aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/","title":{"rendered":"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae"},"content":{"rendered":"

\nStudy Evaluates a 3rd Generation Multivariate Index Assay for serial monitoring women with a benign pelvic mass as well as the expansion of our development of our proteogenomic test for early-stage detection of ovarian cancer in high risk Ovarian Cancer patients
\n<\/h2>\n
\n

AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health, Inc. (Nasdaq: AWH),<\/strong>\u00a0a bioanalytical-based women\u2019s health company focused on gynecologic disease and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, the largest private Healthcare Provider in New York State, today announced the start of a prospective Clinical Study for Ovarian Cancer Risk Detection. Northwell Health treats over 2 million patients annually and employs over 16,000 credentialled physicians.<\/p>\n

The study will enroll over 600 prospective women with adnexal masses. The study will also enroll over 2000 women at high risk for Ovarian Cancer, either due to a personal or family history of cancer or are carriers of a germline variant associated with hereditary breast and ovarian cancer syndrome. Ovarian cancer risk will be assessed by both CA125 and Aspira\u2019s OVASight proprietary algorithm. The primary objective is to increase our total trial enrollment to validate the serial monitoring aspect of the OVASight algorithm in women who present with an adnexal mass. The secondary endpoint is to test additional genomic markers to develop a proteogenomic test for early-stage detection of ovarian cancer. This study will support and collect different biological targets and clinical data metrics to support our innovation pipeline for test development of early diagnosis of ovarian, and other gynecological cancers. \u201cHaving testing options for women with benign masses to monitor them over time, as well as having a solution for assessing risk in high-risk women will provide meaningful insights for providers treating these women,\u201d said Elena Ratner, MD, Gynecologic Oncologist and Global Chief Medical Advisor, Clinical and Translational Medicine<\/p>\n

\u201cNorthwell Health is proud to work with Aspira on this important clinical study,\u201d stated the Principal Investigator of the trial, Dr. Gary L. Goldberg, Vice Chair for Research, Department of Obstetrics and Gynecology, at Northwell Health and researcher at the Feinstein Institutes. \u201cAs clinicians we need innovative and reliable testing options for women and our hope is this study will provide key insights for diagnosing and treating women who are high risk for developing ovarian cancer.\u201d<\/p>\n

Aspira Women\u2019s Health has over 10 years of experience developing Ovarian Cancer Risk Assessment tests with its proprietary, FDA-Cleared OVA1\u00ae and OVERA\u00ae multivariate index assay\u2019s. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the only gender-specific cancer with an over 50 percent mortality rate impacting women of all ages and ethnicities.<\/p>\n

\u201cThis study is twofold, one is to vastly increase our enrollment to clinically validate the serial monitoring aspect OVASight test for all women who present with a mass and hereditary breast and ovarian cancer syndrome, and second, enrich our research and innovation pipeline,\u201d said Lesley Northrop, PhD, FACMG, Chief Scientific Officer, Aspira Women\u2019s Health. \u201cI am incredibly excited to work with the Feinstein Institutes in enhancing our biobank of biological samples and clinical data metrics. This will allow us the ability to evaluate additional biomarkers including ctDNA, RNA and proteins to apply as a multi-modal approach in early diagnosis of ovarian cancer as a liquid-biopsy based test.\u201d<\/p>\n

\n
\n About the Feinstein Institutes <\/em>
\n <\/strong>
\n
\n
\n The Feinstein Institutes for Medical Research<\/em>
\n <\/a>
\n is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine \u2013 a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit <\/em>
\n
\n http:\/\/feinstein.northwell.edu<\/em>
\n <\/a>
\n and follow us on <\/em>
\n
\n LinkedIn<\/em>
\n <\/a>
\n . <\/em>\n <\/p>\n

\n About Aspira Women\u2019s Health Inc.<\/strong>
\n
Aspira Women\u2019s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women\u2019s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women\u2019s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1\u00ae plus includes our FDA-cleared products, OVA1\u00ae and OVERA\u00ae, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXTM<\/sup> testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women\u2019s Health is delivering a portfolio of pelvic mass products over a patient\u2019s lifetime with our cutting-edge research. The next generation of products in development are OVASightTM<\/sup> and EndoCheckTM<\/sup>. Visit our website for more information at www.aspirawh.com<\/a>.<\/p>\n

\n Investor Relations Contact:<\/strong>\n <\/p>\n

Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com<\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Study Evaluates a 3rd Generation Multivariate Index Assay for serial monitoring women with a benign pelvic mass as well as the expansion of our development of our proteogenomic test for early-stage detection of ovarian cancer in high risk Ovarian Cancer patients AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health, Inc. (Nasdaq: AWH),\u00a0a bioanalytical-based women\u2019s health company focused on gynecologic disease and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, the largest private Healthcare Provider in New York State, today announced the start of a prospective Clinical Study for Ovarian Cancer Risk Detection. Northwell Health treats over 2 million patients annually and employs over 16,000 credentialled physicians. The study will enroll over 600 prospective … <\/p>\n

Continue reading “Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-492402","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Study Evaluates a 3rd Generation Multivariate Index Assay for serial monitoring women with a benign pelvic mass as well as the expansion of our development of our proteogenomic test for early-stage detection of ovarian cancer in high risk Ovarian Cancer patients AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health, Inc. (Nasdaq: AWH),\u00a0a bioanalytical-based women\u2019s health company focused on gynecologic disease and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, the largest private Healthcare Provider in New York State, today announced the start of a prospective Clinical Study for Ovarian Cancer Risk Detection. Northwell Health treats over 2 million patients annually and employs over 16,000 credentialled physicians. The study will enroll over 600 prospective … Continue reading "Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-12T20:11:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae\",\"datePublished\":\"2021-05-12T20:11:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/\"},\"wordCount\":873,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/\",\"name\":\"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==\",\"datePublished\":\"2021-05-12T20:11:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/","og_locale":"en_US","og_type":"article","og_title":"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae - Market Newsdesk","og_description":"Study Evaluates a 3rd Generation Multivariate Index Assay for serial monitoring women with a benign pelvic mass as well as the expansion of our development of our proteogenomic test for early-stage detection of ovarian cancer in high risk Ovarian Cancer patients AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health, Inc. (Nasdaq: AWH),\u00a0a bioanalytical-based women\u2019s health company focused on gynecologic disease and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, the largest private Healthcare Provider in New York State, today announced the start of a prospective Clinical Study for Ovarian Cancer Risk Detection. Northwell Health treats over 2 million patients annually and employs over 16,000 credentialled physicians. The study will enroll over 600 prospective … Continue reading \"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-12T20:11:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae","datePublished":"2021-05-12T20:11:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/"},"wordCount":873,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/","name":"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==","datePublished":"2021-05-12T20:11:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTI2MiM0MTgwODM2IzUwMDA0NTYzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-initiates-prospective-clinical-study-for-benign-risk-monitoring-and-high-risk-early-ovarian-cancer-detection-with-northwell-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aspira Women\u2019s Health Initiates Prospective Clinical Study for\u00a0Benign Risk Monitoring and High Risk Early Ovarian Cancer\u00a0Detection with Northwell Health\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/492402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=492402"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/492402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=492402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=492402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=492402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}